Doxycycline Hyclate Injectable (Investigational)

Preclinical

Doxycycline Hyclate Injectable (Investigational) is one of 4 therapeutic programs targeting Ehlers-Danlos syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ehlers-Danlos SyndromeNot yet recruiting

Ehlers-Danlos SyndromePreclinical

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Ehlers-Danlos Syndrome

#DrugCompanyPhaseTrials

Enzastaurin

Eli Lilly

Phase 3

1 2

Pitocin

RRetrophin

Phase 2

1 3

Riboflavin

CCornea and Laser Eye Institute

Preclinical

1 4

Doxycycline Hyclate Injectable (Investigational)

MManhattan Pain Medicine, PLLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalNot yet recruiting

Ehlers-Danlos Syndrome

NCT07688096

Clinical

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

Regenerative Medicine for Joint Hypermobility and Instability: A Prospective, Open-Label, Single-Arm, Step-Care Clinical Study

Not yet recruiting·MManhattan Pain Medicine, PLLC·Preclinical·NCT07688096·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxycycline Hyclate Injectable (Investigational). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Doxycycline Hyclate Injectable (Investigational). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Manhattan Pain Medicine, PLLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MManhattan Pain Medicine, PLLC

Doxycycline Hyclate Injectable (Investigational)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

References

Drug Info

Quick Facts

Related News